Stem Cell Therapy for Long COVID

What This Article Covers

Long COVID (also called post-acute sequelae of COVID-19, or PASC) leaves millions of people with persistent fatigue, brain fog, and other symptoms months after infection, and conventional medicine still has no dedicated cure. Because mesenchymal stem cells (MSCs) and related cord blood-derived stem cell products calm inflammation, researchers have begun testing them for Long COVID fatigue. This article covers how the therapy is thought to work, what the small but growing clinical evidence shows, and who might realistically be a candidate — while being clear that no stem cell product is FDA-approved for Long COVID.

How It's Thought to Work

Mesenchymal stem cells (MSCs) are adult stem cells typically harvested from umbilical cord tissue, cord blood, bone marrow, or fat and delivered by IV infusion. They don't appear to "cure" Long COVID by replacing damaged cells. Instead, researchers believe their main effect is immunomodulatory: MSCs release signaling molecules that can dial down chronic, low-grade inflammation and rebalance an overactive immune response — both suspected drivers of Long COVID's hallmark fatigue, brain fog, and post-exertional malaise. A related but distinct approach uses cord blood-derived hematopoietic progenitor cell products, which are not the same cell type as MSCs but are being studied for similar anti-inflammatory effects. Because Long COVID appears to have several biological subtypes — one research team links mitochondrial dysfunction to the fatigue-predominant form — scientists are especially interested in whether stem cell therapies can target fatigue specifically.

What the Evidence Shows

The evidence is early but more concrete than in many other stem cell applications, and one recent trial result is genuinely encouraging. In a phase IIa randomized, placebo-controlled trial published in eClinicalMedicine, 30 adults with post-COVID syndrome were randomized 2:1 to receive three IV infusions of a cord blood-derived stem cell product (REGENECYTE) or placebo over six weeks. By week 26, treated participants' fatigue scores on a validated questionnaire dropped from an average of 6.8 to 1.0, versus a much smaller decline (7.7 to 5.2) with placebo — a statistically significant difference (p<0.001). Quality-of-life scores improved too, and only mild, self-limited side effects were reported, with no serious adverse events. It's a real signal of benefit, backed by a placebo arm — rare in this field.

That said, it's one small, single-site trial of 30 people, cognitive scores didn't improve significantly, and the product is a cord blood-derived cell therapy rather than a classic MSC product. Separately, a four-year follow-up of MSC trials in severe COVID-19 survivors (Journal of Translational Medicine) found that patients who'd received umbilical cord MSCs during acute illness later developed chronic fatigue-type post-COVID syndrome less often than those on standard care alone (41.3% versus 66.1%, p=0.003) — a possible preventive effect from MSCs given during acute illness, not treatment of established Long COVID.

A 2024 review in Biomolecules focused on neurological Long COVID symptoms was more cautious, concluding that while over 100 COVID-related MSC trials exist, dedicated trials testing MSCs against long-COVID neurological symptoms are still "urgently needed," with no clinical trial evidence yet demonstrating efficacy for those symptoms. A Phase 1 dose-escalation trial of cord blood-derived stem cells for Long COVID/PASC (NCT06156241) is currently recruiting at UTHealth Houston. Overall: one promising placebo-controlled result, a suggestive prevention signal, and reviewer consensus that much more data is needed.

Who Might Be a Candidate

• Adults with persistent, disabling post-COVID fatigue that hasn't responded to standard supportive care (pacing, rehabilitation, symptom-targeted treatment)
• Those who meet a study's eligibility criteria and want to enroll in a registered trial, such as the ongoing NCT06156241 Phase 1 study, rather than pay an unregulated clinic
• People without typical trial exclusions, such as active malignancy, uncontrolled autoimmune disease, or pregnancy
• Patients who understand this is not a cure and want to reduce fatigue severity, not reverse every Long COVID symptom
• Anyone who has weighed the real risks, unknowns, and costs with a knowledgeable clinician — and is wary of clinics marketing unproven "stem cell cures" outside legitimate trials

Bottom Line

Stem cell therapy for Long COVID is one of the more evidence-backed corners of regenerative medicine right now, with a small but real placebo-controlled trial showing meaningful fatigue improvement — genuinely good news worth taking seriously. But "promising" is not the same as "proven": the strongest result comes from 30 patients at a single site, a related signal comes from a secondary analysis of an acute-COVID trial, and independent reviewers say dedicated efficacy trials are still needed. No stem cell product is FDA-approved for Long COVID, and patients are best served by enrolling in a registered clinical trial rather than seeking treatment from clinics selling unproven infusions.